No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
RPTX Repare Therapeutics
- 3.360
- +0.100+3.07%
Close Apr 23 16:00 ET
141.73MMarket Cap-1506P/E (TTM)
3.430High3.240Low175.63KVolume3.240Open3.260Pre Close588.80KTurnover1.18%Turnover RatioLossP/E (Static)42.18MShares13.85052wk High0.67P/B50.13MFloat Cap2.98052wk Low--Dividend TTM14.92MShs Float46.440Historical High--Div YieldTTM5.83%Amplitude2.980Historical Low3.352Avg Price1Lot Size
Pre-Market
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Buy Rating Reaffirmed for Repare Therapeutics on Strong Clinical Outlook and Attractive Valuation
Repare Therapeutics Inc.'s (NASDAQ:RPTX) Market Cap Dropped US$21m Last Week; Private Equity Firms Bore the Brunt
Roche's Lymphoma Drug With Chemo Extends Survival In Pretreated Patients
Monday, Roche Holdings AG (OTC:RHHBY) announced topline data from Phase 3 STARGLO study of Columvi (glofitamab) in combination with gemcitabine plus oxaliplatin (GemOx) versus MabThera/Rituxan (rituxi
Form 144 | Repare Therapeutics(RPTX.US) Officer Proposes to Sell 481.42K in Common Stocks
SEC FILLINGS DISCLOSED/ Mar 26, $Repare Therapeutics(RPTX.US)$ Officer Segal Lloyd Mitchell intends to sell 99,466 shares of its common stock on Mar 26, with a total market value of approximately $481
Repare Therapeutics Inc. (RPTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages...
Repare Therapeutics Inc. (RPTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
NEW YORK--(BUSINESS WIRE)--$RPTX #classaction--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Repare Therapeutics Inc. ("Repare"
Comments
Some dates to watch for!
$Repare Therapeutics(RPTX.US$ Especially the MINOTAUR phase 1 Data release soon? 2024 Outlook:
•Initiate a Phase 1/1b clinical trial of lunresertib and Debio 0123, a WEE1 inhibitor, in the first half of 2024 as a fourth arm of the ongoing MYTHIC clinical trial. •Report initial ...
•Initiate a Phase 1/1b clinical trial of lunresertib and Debio 0123, a WEE1 inhibitor, in the first half of 2024 as a fourth arm of the ongoing MYTHIC clinical trial. •Report initial ...
Repare Therapeutics' low P/S ratio is likely due to poor revenue performance and negative growth forecasts. The company's poor outlook compared to other industry players justifies its low P/S ratio.
1
The company's falling revenue and high cash burn relative to its market value are concerning. Despite a promising cash runway, the cash burn situation is considered a bit risky and causes some nervousness about the stock.
Repare Therapeutics' shrinking revenues and declining revenue forecast could challenge its P/S maintenance, possibly hindering significant share price growth. Its low P/S is acceptable to shareholders considering future revenue stagnation.
$Repare Therapeutics(RPTX.US$ Repare Therapeutics Announces Positive Initial Data from Phase 1 MYTHIC Clinical Trial Evaluating Lunresertib Alone and in Combination with Camonsertib
2
6
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg